Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer’s biosimilar to Humira®

July 18, 2024

https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-goodrx-announce-exclusive-patient-affordability-initiative-for-adalimumab-adbm-injection-boehringers-biosimilar-to-humira-302199865.html

Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer’s biosimilar to Humira®
/PRNewswire/ — Boehringer Ingelheim and GoodRx (Nasdaq:GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability…
https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-goodrx-announce-exclusive-patient-affordability-initiative-for-adalimumab-adbm-injection-boehringers-biosimilar-to-humira-302199865.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.